News release

Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").

Pursuant to the Offering, the Selling Shareholders sold an aggregate of 25,000,000 Common Shares at a price of $34.00 per Common Share, for total gross proceeds to the Selling Shareholders of $850,000,000. The Company did not receive any proceeds from the Offering.

The Offering was made through a syndicate of underwriters led by RBC Capital Markets, TD Securities Inc. and Scotiabank, as joint lead bookrunners, BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, and CIBC Capital Markets, ATB Cormark Capital Markets, Desjardins Capital Markets, National Bank Capital Markets, Raymond James, Bloom Burton Securities Inc., Canaccord Genuity Corp., Stifel and Paradigm Capital Inc.

The Common Shares were offered by way of a prospectus supplement dated September 15, 2026 (the “Prospectus Supplement”) to the final short form base shelf prospectus of the Company dated August 18, 2026 (the “Shelf Prospectus”) in all of the provinces and territories of Canada and were also offered by way of private placement in the United States and internationally as permitted in accordance with applicable securities laws. Each of the Prospectus Supplement and the Shelf Prospectus has been filed and is available under the Company's profile on SEDAR+ at www.sedarplus.ca.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Apotex in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered, sold or delivered, directly or indirectly, in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to certain exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws.

About Apotex

Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws, including statements about the business of Apotex. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under “Risk Factors” in the Company's supplemented PREP prospectus dated June 10, 2026. Apotex undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws.

For further information, please contact: [email protected]